This article discusses peptides as research compounds. It is not medical advice.
GLP-1 receptor agonists drive weight loss by suppressing appetite and slowing gastric emptying. The result is a sustained caloric deficit that reliably reduces body mass. What the agonists do not do is distinguish between adipose and skeletal muscle when that deficit persists. Clinical trials report lean-tissue losses in the neighbourhood of 25–40% of total weight shed (Wilding 2021), a figure that rises when protein intake falls below 1.2 g/kg or resistance training is absent. The loss is metabolically costly. Muscle consumes energy at rest, regulates glucose disposal, and anchors physical resilience. Once catabolised, it rebuilds slowly.
NAD+ occupies a different axis. Nicotinamide adenine dinucleotide exists in every cell as both an electron shuttle and a substrate for enzymes that govern mitochondrial respiration, DNA repair, and circadian rhythm. When NAD+ pools contract, ATP synthesis falters, sirtuins lose activity, and the cell defaults to glycolysis even when oxygen is plentiful. Muscle fibres, rich in mitochondria, are especially sensitive to NAD+ availability. Precursor supplementation with nicotinamide riboside or nicotinamide mononucleotide has been shown to restore NAD+ levels in aged or metabolically stressed tissue (Yoshino 2018), raising the question of whether similar restoration might protect lean mass during prolonged caloric restriction.
Why Muscle Atrophies Under Caloric Deficit
Skeletal muscle adapts to energy scarcity by downregulating protein synthesis and upregulating proteolysis. The ubiquitin–proteasome system and autophagy-lysosome pathways dismantle myofibrillar proteins into amino acids, which the liver converts to glucose or oxidises for ATP. This process accelerates when circulating insulin remains low and cortisol rises, a hormonal profile common to both fasting and pharmacologically induced anorexia.
GLP-1 agonists do not block this cascade. They reduce food intake but offer no direct signal to preserve contractile tissue. Resistance exercise provides one such signal by activating mTORC1 and satellite-cell proliferation, yet adherence to structured training during appetite suppression is inconsistent. The muscle that remains after months of treatment often shows reduced cross-sectional area on MRI and diminished force output on dynamometry (Murton 2015).
NAD+ influences this balance at the mitochondrial level. Sirtuins, particularly SIRT1 and SIRT3, require NAD+ as a cosubstrate to deacetylate targets involved in oxidative metabolism and mitochondrial biogenesis. When NAD+ is abundant, PGC-1α activity rises, promoting the transcription of genes encoding respiratory-chain subunits and antioxidant enzymes. The result is a muscle fibre better equipped to meet energy demand through fat oxidation rather than protein catabolism.
NAD+ Precursors and Mitochondrial Function in Muscle
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are phosphorylated and adenylated along the salvage pathway to regenerate NAD+. Oral dosing with NR in the range of 500–1000 mg per day has been shown to elevate whole-blood NAD+ by 40–90% within two weeks (Trammell 2016). Muscle biopsies from NR-supplemented subjects reveal increased expression of oxidative-phosphorylation genes and higher mitochondrial respiration rates when measured ex vivo.
In rodent models of caloric restriction, NMN administration (300 mg/kg) preserved gastrocnemius mass and grip strength compared to vehicle controls, even when total body weight declined equivalently (Mills 2016). The protective effect correlated with sustained NAD+/NADH ratios and reduced markers of autophagy flux, suggesting that energy sufficiency at the mitochondrial level dampened the need for amino-acid mobilisation.
Human data remain sparse but directionally consistent. A 2021 trial in older adults combined NR supplementation with moderate caloric restriction over 12 weeks. Dual-energy X-ray absorptiometry showed fat-mass reduction without significant lean-mass loss, and muscle-biopsy transcriptomics revealed upregulation of genes in the OXPHOS and fatty-acid oxidation pathways (Elhassan 2019). The implication is that when muscle can efficiently burn lipid, it spares its own protein.
Thymalin and the Immune–Metabolic Interface
Thymalin, a polypeptide extract of thymic tissue, has been studied primarily in the context of immune senescence and tissue repair. Its mechanism involves modulation of T-cell differentiation and cytokine signalling, but recent work suggests a secondary effect on skeletal-muscle homeostasis during catabolic stress.
In a murine model of dexamethasone-induced atrophy, Thymalin administration (10 μg subcutaneously, daily for 10 days) attenuated the loss of myofibre diameter and preserved grip strength relative to saline controls (Khavinson 2016). Immunohistochemistry showed reduced infiltration of pro-inflammatory macrophages and lower expression of MuRF1 and atrogin-1, E3 ubiquitin ligases that tag muscle proteins for degradation.
The proposed pathway involves Thymalin's suppression of TNF-α and IL-6, cytokines that activate NF-κB and FOXO transcription factors upstream of proteolytic gene expression. By dampening systemic inflammation, Thymalin may indirectly reduce the catabolic drive that accompanies prolonged caloric deficit, particularly in the setting of GLP-1-mediated weight loss where adipose remodelling can trigger low-grade inflammation.
Whether Thymalin synergises with NAD+ precursors is an open question. Both target distinct nodes in the muscle-atrophy network, one metabolic and one immunological, raising the possibility of additive or complementary effects when combined.
Mitochondrial Peptides: MOTS-c and Vesugen
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, translated in the cytosol, and imported back into mitochondria where it regulates metabolic gene expression. Its primary action is to inhibit the folate cycle, redirecting one-carbon units toward purine synthesis and away from methionine salvage, a shift that enhances AMPK activation and insulin sensitivity (Lee 2015).
In skeletal muscle, MOTS-c administration (5 mg/kg intraperitoneally in mice) increased glucose uptake independent of insulin and improved running endurance by something like 30% over vehicle controls. Muscle fibres showed greater mitochondrial density and elevated NAD+/NADH ratios, suggesting that MOTS-c and NAD+ precursors may converge on overlapping pathways. The peptide's ability to preserve muscle function during metabolic stress has not been tested directly in caloric-restriction models, but its metabolic fingerprint aligns with the goal of maintaining oxidative capacity when energy intake is constrained.
Vesugen, a tripeptide (Lys-Glu-Asp), has been characterised as a vascular bioregulator with effects on endothelial nitric-oxide synthase and capillary density. Muscle perfusion is a determinant of nutrient delivery and waste clearance, both relevant to protein turnover. Limited rodent data suggest that Vesugen may support angiogenesis in ischaemic tissue, but its role in preserving lean mass during weight loss has not been explored in controlled trials.
Interpreting the Evidence
The case for NAD+ precursors rests on a mechanistic foundation: muscle that can generate ATP efficiently from fat oxidation is less likely to catabolise its own contractile proteins. Clinical evidence in humans is still emerging, but the rodent and early-phase human data are directionally consistent. Thymalin adds an immune-modulation layer that may address the inflammatory component of muscle wasting, particularly relevant when rapid fat loss triggers adipokine dysregulation.
MOTS-c and Vesugen occupy adjacent but less-developed territories. The former's AMPK-activating and NAD+-boosting effects are plausible complements to NR or NMN, while the latter's vascular effects remain speculative in the context of lean-tissue preservation. None of these compounds replicate the anabolic signal provided by resistance training or adequate protein intake, both of which remain the most robust interventions for muscle retention during caloric deficit.
For those interested in the broader metabolic implications, the comparison between NAD+ and GLP-1 pathways in longevity offers additional context on how these systems diverge and occasionally intersect.
Practical Considerations
NAD+ precursors are generally well tolerated at doses up to 1000 mg daily, with mild nausea reported in a subset of users at higher intakes. Thymalin protocols in the literature typically involve subcutaneous injection at 5–10 μg per dose, though human pharmacokinetic data are limited. MOTS-c has been administered subcutaneously in research settings at doses extrapolated from rodent mg/kg figures, usually in the range of 5–15 mg per injection.
Timing relative to GLP-1 agonist administration has not been systematically studied. Given that NAD+ precursors require several days to weeks to elevate tissue NAD+ pools, concurrent use from the outset of weight-loss therapy would be the logical approach if the goal is to prevent rather than reverse lean-tissue loss.
Monitoring lean mass via DEXA or bioimpedance at regular intervals provides objective feedback, though these methods carry measurement error in the range of 2–5% for lean tissue. Functional assessments such as grip strength or timed stair climb may offer complementary data, particularly in older adults where sarcopenia risk is elevated.
Closing Remarks
GLP-1 agonists are effective tools for weight reduction but indifferent to tissue composition. NAD+ precursors address a metabolic bottleneck that may limit muscle catabolism when energy is scarce, while Thymalin and related peptides target inflammatory and vascular pathways that influence muscle homeostasis. The evidence base is incomplete, but the mechanistic rationale is coherent. For individuals navigating prolonged caloric deficits, the combination of NAD+ support, structured resistance training, and adequate protein remains the most defensible strategy for preserving the muscle that determines metabolic health long after the scale stops moving.